174 related articles for article (PubMed ID: 20962515)
1. Reactive metabolites and AGE/RAGE-mediated cellular dysfunction affect the aging process: a mini-review.
Fleming TH; Humpert PM; Nawroth PP; Bierhaus A
Gerontology; 2011; 57(5):435-43. PubMed ID: 20962515
[TBL] [Abstract][Full Text] [Related]
2. Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains.
Kuhla B; Boeck K; Schmidt A; Ogunlade V; Arendt T; Münch G; Lüth HJ
Neurobiol Aging; 2007 Jan; 28(1):29-41. PubMed ID: 16427160
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases.
Grillo MA; Colombatto S
Amino Acids; 2008 Jun; 35(1):29-36. PubMed ID: 18008028
[TBL] [Abstract][Full Text] [Related]
4. Age-dependent changes of glyoxalase I expression in human brain.
Kuhla B; Boeck K; Lüth HJ; Schmidt A; Weigle B; Schmitz M; Ogunlade V; Münch G; Arendt T
Neurobiol Aging; 2006 Jun; 27(6):815-22. PubMed ID: 15950319
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress and aging: is methylglyoxal the hidden enemy?
Desai KM; Chang T; Wang H; Banigesh A; Dhar A; Liu J; Untereiner A; Wu L
Can J Physiol Pharmacol; 2010 Mar; 88(3):273-84. PubMed ID: 20393592
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background.
Kalousová M; Zima T; Tesar V; Dusilová-Sulková S; Skrha J
Mutat Res; 2005 Nov; 579(1-2):37-46. PubMed ID: 16084533
[TBL] [Abstract][Full Text] [Related]
7. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
Yamagishi S
Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
[TBL] [Abstract][Full Text] [Related]
8. RAGE upregulation and nuclear factor-kappaB activation associated with ageing rat cardiomyocyte dysfunction.
Gao ZQ; Yang C; Wang YY; Wang P; Chen HL; Zhang XD; Liu R; Li WL; Qin XJ; Liang X; Hai CX
Gen Physiol Biophys; 2008 Sep; 27(3):152-8. PubMed ID: 18981529
[TBL] [Abstract][Full Text] [Related]
9. A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H
Med Hypotheses; 2007; 69(2):338-40. PubMed ID: 17329034
[TBL] [Abstract][Full Text] [Related]
10. Genetics vs. entropy: longevity factors suppress the NF-kappaB-driven entropic aging process.
Salminen A; Kaarniranta K
Ageing Res Rev; 2010 Jul; 9(3):298-314. PubMed ID: 19903538
[TBL] [Abstract][Full Text] [Related]
11. Female reproductive dysfunction during ageing: role of methylglyoxal in the formation of advanced glycation endproducts in ovaries of reproductively-aged mice.
Tatone C; Carbone MC; Campanella G; Festuccia C; Artini PG; Talesa V; Focarelli R; Amicarelli F
J Biol Regul Homeost Agents; 2010; 24(1):63-72. PubMed ID: 20385072
[TBL] [Abstract][Full Text] [Related]
12. Prevention of dicarbonyl-mediated advanced glycation by glyoxalases: implication in skin aging.
Radjei S; Friguet B; Nizard C; Petropoulos I
Biochem Soc Trans; 2014 Apr; 42(2):518-22. PubMed ID: 24646271
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products (AGE) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce NF-kappaB activation.
Matsunaga N; Anan I; Forsgren S; Nagai R; Rosenberg P; Horiuchi S; Ando Y; Suhr OB
Acta Neuropathol; 2002 Nov; 104(5):441-7. PubMed ID: 12410391
[TBL] [Abstract][Full Text] [Related]
14. Rutin metabolites: novel inhibitors of nonoxidative advanced glycation end products.
Pashikanti S; de Alba DR; Boissonneault GA; Cervantes-Laurean D
Free Radic Biol Med; 2010 Mar; 48(5):656-63. PubMed ID: 19969069
[TBL] [Abstract][Full Text] [Related]
15. RAGE in inflammation: a new therapeutic target?
Bierhaus A; Stern DM; Nawroth PP
Curr Opin Investig Drugs; 2006 Nov; 7(11):985-91. PubMed ID: 17117586
[TBL] [Abstract][Full Text] [Related]
16. Potential of glycative stress targeting for cancer prevention.
Piperi C; Adamopoulos C; Papavassiliou AG
Cancer Lett; 2017 Apr; 390():153-159. PubMed ID: 28111136
[TBL] [Abstract][Full Text] [Related]
17. Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics.
Rabbani N; Xue M; Thornalley PJ
Glycoconj J; 2016 Aug; 33(4):513-25. PubMed ID: 27406712
[TBL] [Abstract][Full Text] [Related]
18. RAGE, vascular tone and vascular disease.
Farmer DG; Kennedy S
Pharmacol Ther; 2009 Nov; 124(2):185-94. PubMed ID: 19616578
[TBL] [Abstract][Full Text] [Related]
19. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(2):392-4. PubMed ID: 15922119
[TBL] [Abstract][Full Text] [Related]
20. Receptor for advanced glycation end products and age-related macular degeneration.
Howes KA; Liu Y; Dunaief JL; Milam A; Frederick JM; Marks A; Baehr W
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3713-20. PubMed ID: 15452081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
